Known targets — ChEMBL curated mechanism
ABL1ACEACHEACVR1ADRA1AADRA1BADRA1DADRA2AADRA2BADRA2CADRB1ADRB2ADRB3AGTR1ALKAVPR1AAVPR2BCHEBCRCA2CACNA1ACACNA1BCACNA1CCACNA1DCACNA1ECACNA1FCACNA1GCACNA1HCACNA1ICACNA1SCACNA2D1CACNA2D2CACNA2D3CACNA2D4CACNB1CACNB2CACNB3CACNB4CACNG1CACNG2CACNG3CACNG4CACNG5CACNG6CACNG7CACNG8CALCRLCASRCCR5CDK4CDK6CFBCHRM1CHRM2CHRM3CHRM4CHRM5CHRNA1CHRNA3CHRNA7CHRNB1CHRNB4CHRNDCHRNECHRNGCOXFA4COXFA4L2CRBNCSF1RCUL4ACYP19A1DDB1DPP4DRD1DRD2DRD3DRD4EDNRAEGFREML4ERBB2ERBB4ESR1ESR2FGFR1FGFR3FLT1FLT3FLT4GAAGABRA1GABRA2GABRA3GABRA4GABRA5GABRA6GABRB1GABRB2GABRB3GABRDGABREGABRG1GABRG2GABRG3GABRPGABRQGHSRGLAGNRHRGPD2GRIN1GRIN2AGRIN2BGRIN2CGRIN2DGRIN3AGRIN3BGSTP1HCN4HCRTR1HCRTR2HDAC1HDAC10HDAC11HDAC2HDAC3HDAC4HDAC5HDAC6HDAC7HDAC8HDAC9HRH1HRH2HRH3HSD11B1HSP90AA1HSP90AB1HTR1AHTR1BHTR1DHTR1EHTR1FHTR2AHTR2BHTR2CHTR3AHTR3BHTR3CHTR3DHTR3EHTR4HTR5AHTR6HTR7IMPDH1IMPDH2ITGA2BITGB3ITKJAK1JAK2KCNA1KCNA10KCNA2KCNA3KCNA4KCNA5KCNA6KCNA7KCNB1KCNB2KCNC1KCNC2KCNC3KCNC4KCND1KCND2KCND3KCNF1KCNG1KCNG2KCNG3KCNG4KCNH1KCNH2KCNH3KCNH4KCNH5KCNH6KCNH7KCNH8KCNJ2KCNJ3KCNJ5KCNK3KCNK9KCNQ1KCNQ2KCNQ3KCNQ4KCNQ5KCNS1KCNS2KCNS3KCNV1KCNV2KDRKITKLKB1LCKMMAOAMAOBMAPK14METMMP1MMP13MMP7MMP8MT-ND1MT-ND2MT-ND3MT-ND4MT-ND4LMT-ND5MT-ND6NDUFA1NDUFA10NDUFA11NDUFA12NDUFA13NDUFA2NDUFA3NDUFA5NDUFA6NDUFA7NDUFA8NDUFA9NDUFAB1NDUFAF1NDUFAF2NDUFAF3NDUFAF4NDUFB1NDUFB10NDUFB11NDUFB2NDUFB3NDUFB4NDUFB5NDUFB6NDUFB7NDUFB8NDUFB9NDUFC1NDUFC2NDUFS1NDUFS2NDUFS3NDUFS4NDUFS5NDUFS6NDUFS7NDUFS8NDUFV1NDUFV2NDUFV3NR3C1NS5ANTRK1NTRK2NTRK3ODC1OPRD1OPRK1OPRM1P2RY12PAHPARP1PDE3APDE3BPDE4APDE4BPDE4CPDE4DPDE5APDE7APDE7BPDE8APDE8BPDGFRAPDGFRBPIK3CAPIK3CDPNPPOLA1POLA2POLD1POLD2POLD3POLD4POLEPOLE2POLE3PPARGPRIM1PRIM2PRKCAPRKCBPRKCDPRKCEPRKCGPRKCHPRKCIPRKCQPRKCZPRKD1PRKD3PTGS1PTGS2RBX1RENRETROCK1ROCK2RPE65RRM1RRM2RRM2BS1PR1S1PR2S1PR3S1PR4S1PR5SCN10ASCN11ASCN1ASCN2ASCN3ASCN4ASCN5ASCN7ASCN8ASCN9ASCNN1ASCNN1BSCNN1GSIGMAR1SLC18A2SLC6A1SLC6A2SLC6A3SLC6A4SLC9A3SRCTACR1TOP1TOP2ATOP2BTTRTYMPdacAdacBdacCembAfolAftsIgyrAgyrBmrcAmrcBmrdAparCparEpolrplArplBrplCrplDrplErplFrplIrplJrplKrplLrplMrplNrplOrplPrplQrplRrplSrplTrplUrplVrplWrplXrplYrpmArpmBrpmCrpmDrpmErpmE2rpmFrpmGrpmG1rpmG2rpmG3rpmHrpmIrpmJrpsArpsBrpsCrpsDrpsErpsFrpsGrpsHrpsIrpsJrpsKrpsLrpsMrpsNrpsOrpsPrpsQrpsRrpsSrpsTrpsUykgMykgO
The experimentally established mechanism targets of Carpipramine. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD3 known ✓ | P35462 | 8/20 | 0.98 |
| ▸ | CHRM2 known ✓ | P08172 | 6/20 | 0.98 |
| ▸ | CHRM1 known ✓ | P11229 | 6/20 | 0.98 |
| ▸ | ADRA1A known ✓ | P35348 | 3/20 | 0.98 |
| ▸ | HTR1A known ✓ | P08908 | 2/20 | 0.98 |
| ▸ | ADRA2A known ✓ | P08913 | 2/20 | 0.98 |
| ▸ | DRD1 known ✓ | P21728 | 2/20 | 0.98 |
| ▸ | SLC6A4 known ✓ | P31645 | 2/20 | 0.98 |
| ▸ | OPRM1 known ✓ | P35372 | 2/20 | 0.98 |
| ▸ | SLC6A3 known ✓ | Q01959 | 2/20 | 0.98 |
| ▸ | KCNH2 known ✓ | Q12809 | 2/20 | 0.98 |
| ▸ | HRH3 known ✓ | Q9Y5N1 | 2/20 | 0.98 |
| ▸ | SLC6A2 known ✓ | P23975 | 1/20 | 0.98 |
| ▸ | DRD4 known ✓ | P21917 | 7/20 | 0.47 |
| ▸ | DRD2 known ✓ | P14416 | 6/20 | 0.46 |
| ▸ | CHRM4 known ✓ | P08173 | 5/20 | 0.46 |
| ▸ | CHRM5 known ✓ | P08912 | 5/20 | 0.46 |
| ▸ | CHRM3 known ✓ | P20309 | 5/20 | 0.46 |
| ▸ | ADRB2 known ✓ | P07550 | 1/20 | 0.44 |
| ▸ | ADRB1 known ✓ | P08588 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Carpipramine SCHEMBL365672 | 1.00 | DRD3 (0.98) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL969082 | 0.99 | DRD3 (0.96) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL29356300 | 0.99 | DRD3 (0.96) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL17747956 | 0.99 | DRD3 (0.96) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL17747957 | 0.99 | DRD3 (0.96) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL29913255 | 0.99 | DRD3 (1.00) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL27478838 | 0.99 | DRD3 (1.00) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL34949 | 0.99 | DRD3 (1.00) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL7353292 | 0.98 | DRD3 (0.98) | DRD3CHRM2CHRM1ADRA1AHTR1A | |
| Carpipramine SCHEMBL1648924 | 0.96 | DRD3 (0.94) | DRD3CHRM2CHRM1ADRA1AHTR1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 52 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3178471-B1 | PREPARATION METHOD OF DRUG-CONTAINING SUSTAINED RELEASE MICROPARTICLES | BCWORLD PHARM CO LTD (KR) | 2019-06-19 | — | — | EP | claimed |
| US-20170216210-A1 | Preparation Method of Drug-Containing Sustained Release Microparticles | BC World Pharm Co.,Ltd. (KR) | 2017-08-03 | — | — | US | claimed |
| EP-3178471-A1 | PREPARATION METHOD OF DRUG-CONTAINING SUSTAINED RELEASE MICROPARTICLES | Bcworld Pharm. Co., Ltd. (KR) | 2017-06-14 | — | — | EP | claimed |
| US-8399007-B2 | Method for formulating a controlled-release pharmaceutical formulation | LANDEC CORPORATION (US) | 2013-03-19 | — | — | US | claimed |
| US-20090252777-A1 | Method for formulating a controlled-release pharmaceutical formulation | LANDEC CORPORATION (US) | 2009-10-08 | — | — | US | claimed |
| EP-1273301-B1 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON SA (CH) | 2006-09-06 | — | — | EP | claimed |
| EP-1273301-A2 | Pharmaceutical preparations based on active ingredients susceptible to illicit administration | ALTERGON S.A. (CH) | 2003-01-08 | — | — | EP | claimed |
| EP-0669128-B1 | SUSTAINED-RELEASE MICROSPHERE CONTAINING ANTIPSYCHOTIC AND PROCESS FOR PRODUCING THE SAME | YOSHITOMI PHARMACEUTICAL (JP) | 2000-01-05 | — | — | EP | claimed |
| US-5871778-A | Sustained release microsphere preparation containing antipsychotic drug | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1999-02-16 | — | — | US | claimed |
| EP-0669128-A1 | SUSTAINED-RELEASE MICROSPHERE CONTAINING ANTIPSYCHOTIC AND PROCESS FOR PRODUCING THE SAME | YOSHITOMI PHARMACEUTICAL INDUSTRIES, LTD. (JP) | 1995-08-30 | — | — | EP | claimed |
| EP-3178471-B1 | PREPARATION METHOD OF DRUG-CONTAINING SUSTAINED RELEASE MICROPARTICLES | BCWORLD PHARM CO LTD (KR) | 2019-06-19 | — | — | EP | disclosed |
| US-20170216210-A1 | Preparation Method of Drug-Containing Sustained Release Microparticles | BC World Pharm Co.,Ltd. (KR) | 2017-08-03 | — | — | US | disclosed |
| EP-3178471-A1 | PREPARATION METHOD OF DRUG-CONTAINING SUSTAINED RELEASE MICROPARTICLES | Bcworld Pharm. Co., Ltd. (KR) | 2017-06-14 | — | — | EP | disclosed |
| US-8956602-B2 | Delivery of drugs | Landec, Inc. (US) | 2015-02-17 | — | — | US | disclosed |
| EP-2298352-B1 | PERCUTANEOUS ABSORPTION ENHANCER AND TRANSDERMAL PREPARATION USING THE SAME | TOA EIYO LTD (JP) | 2015-01-14 | — | — | EP | disclosed |
| US-5176916-A | Plaster layer containing a medicinal ingredient, hydrophobic polymer, absorption promoter, water and a hydrophilic polymer | NITTO ELECTRIC INDUSTRIAL CO., LTD. (JP) | 1993-01-05 | — | — | US | disclosed |
| EP-0452837-A2 | Adhesive device for transdermal administration of an active agent | NITTO DENKO CORPORATION (JP) | 1991-10-23 | — | — | EP | disclosed |
| EP-0424525-A1 | NOVEL AMINES AND THEIR USE | MITSUI PETROCHEMICAL INDUSTRIES, LTD. (JP) | 1991-05-02 | — | — | EP | disclosed |
| EP-0387751-A2 | Medicated plasters | NITTO DENKO CORPORATION (JP) | 1990-09-19 | — | — | EP | disclosed |
| CN-1043319-A | New amine and uses thereof | MITSUI PHARMACEUTICALS (JP) | 1990-06-27 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090252777-A1 | Method for formulating a controlled-release pharmaceutical formulation | LPXN, CYP3A7, LIPA | DRD3 2547/4885CHRM2 886/4885CHRM1 2159/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.